Human Immunoglobulin IgG1-Fc Antibody Biotin Conjugate

<strong>Human Immunoglobulin IgG1-Fc Antibody Biotin Conjugate</strong>_x000D_ <strong>Catalog number:</strong> B2015554_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 50 ug_x000D_ <strong>Molecular Weight or Concentration:</strong> N/A_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20°C_x000D_ <strong>Keywords:</strong> IgG1, ig, immnuoglobuling1, immnuoglobuling 1, immnuoglobuling, immnuoglobuling I_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Howard JF Jr, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, Beydoun S, Garrido FJRR, Piehl F, Rottoli M, Van Damme P, Vu T, Evoli A, Freimer M, Mozaffar T, Ward ES, Dreier T, Ulrichts P, Verschueren K, Guglietta A, de Haard H, Leupin N, Verschuuren JJGM; Efgartigimod MG Study Group. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis Neurology. 2019 Jun 4;92(23):e2661-e2673._x000D_ 2: Pongracz T, Nouta J, Wang W, van Meijgaarden KE, Linty F, Vidarsson G, Joosten SA, Ottenhoff THM, Hokke CH, de Vries JJC, Arbous SM, Roukens AHE, Wuhrer M; BEAT-COVID; COVID-19 groups. Immunoglobulin G1 Fc glycosylation as an early hallmark of severe COVID-19 EBioMedicine. 2022 Apr;78:103957._x000D_ 3: Frank M, Walker RC, Lanzilotta WN, Prestegard JH, Barb AW. Immunoglobulin G1 Fc domain motions: implications for Fc engineering J Mol Biol. 2014 Apr 17;426(8):1799-811._x000D_ 4: Seth Chhabra E, Liu T, Kulman J, Patarroyo-White S, Yang B, Lu Q, Drager D, Moore N, Liu J, Holthaus AM, Sommer JM, Ismail A, Rabinovich D, Liu Z, van der Flier A, Goodman A, Furcht C, Tie M, Carlage T, Mauldin R, Dobrowsky TM, Liu Z, Mercury O, Zhu L, Mei B, Schellenberger V, Jiang H, Pierce GF, Salas J, Peters R. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice Blood. 2020 Apr 23;135(17):1484-1496._x000D_ 5: Shiga Y, Murata D, Sugimoto A, Oshima Y, Tada M, Ishii-Watabe A, Imai K, Tomii K, Takeuchi T, Kagaya S, Sato A. Hinge-Deficient IgG1 Fc Fusion: Application to Human Lactoferrin Mol Pharm. 2017 Sep 5;14(9):3025-3035._x000D_ 6: Yung LY, Tsim KW, Pei G, Wong YH. Immunoglobulin G1 Fc fragment-tagged human opioid receptor-like receptor retains the ability to inhibit cAMP accumulation Biol Signals Recept. 2000 Sep-Oct;9(5):240-7._x000D_ 7: Pfefferkorn LC, Fanger MW. Cross-linking of the high affinity Fc receptor for human immunoglobulin G1 triggers transient activation of NADPH oxidase activity. Continuous oxidase activation requires continuous de novo receptor cross-linking J Biol Chem. 1989 Aug 25;264(24):14112-20._x000D_ 8: Shenoy A, Davis AR, Roberts ET, Amster IJ, Barb AW. Metabolic(15)N labeling of the N-glycosylated immunoglobulin G1 Fc with an engineered Saccharomyces cerevisiae strain J Biomol NMR. 2022 Aug;76(4):95-105._x000D_ 9: Cartron G, Watier H. Obinutuzumab: what is there to learn from clinical trials? Blood. 2017 Aug 3;130(5):581-589._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/17145792">10: Chen J, Li C, Guan Y, Kong Q, Li C, Guo X, Chen Q, Jing X, Lv Z, An Y. Protection of mice from lethal Escherichia coli infection by chimeric human bactericidal/permeability-increasing protein and immunoglobulin G1 Fc gene delivery Antimicrob Agents Chemother. 2007 Feb;51(2):724-31. </a>_x000D_ _x000D_ <strong>Products Related to Human Immunoglobulin IgG1-Fc Antibody Biotin Conjugate can be found at</strong> <a href="https://moleculardepot.com/product-category/Conjugates/"> Conjugates</a>